Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jasper Therapeutics, Inc.JSPR · Entity 7588 | Director | June 06, 2024 | June 10, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jasper Therapeutics, Inc.
Report date June 06, 2024 · Filed June 10, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.41 · Expires 2034-06-06 | Direct | 7,500 |
Reported balance
After 2024-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-06 · Grant · Acquired 7,500 · Balance 7,500 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 06, 2024 Filed Jun 10, 2024 18:30 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $25.41 | $0.00 |
DisclosureSEC source: 0001213900-24-051416 · ownership.xml · derivative · entry 1 French Anna Louise · CIK 0001871871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Voting Common Stock · 7,500 shares Expires 2034-06-06 Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 18:41 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 47,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001213900-23-047567 · ownership.xml · derivative · entry 1 French Anna Louise · CIK 0001871871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,000 Underlying: Voting Common Stock · 47,000 shares Expires 2033-06-07 Read SEC document |
| April 14, 2023 Filed Apr 14, 2023 16:19 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | SaleVoting Common Stock | 7,000 | $1.48 | $10,360.00 |
DisclosureSEC source: 0001213900-23-029901 · ownership.xml · nonDerivative · entry 1 French Anna Louise · CIK 0001871871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,750 F1 · shares: These shares were sold by the Reporting Person solely in order to satisfy certain tax obligations in connection with the issuance of shares of the Issuer's common stock upon the vesting of restricted stock units. Read SEC document |
| October 12, 2022 Filed Oct 13, 2022 19:56 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantVoting Common Stock | 30,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-063934 · ownership.xml · nonDerivative · entry 1 French Anna Louise · CIK 0001871871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,750 F1 · shares: The reported securities are represented by restricted stock units, 1/2 of which shall vest on each of April 12, 2023 and October 12, 2023, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 18:00 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 78,045 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001213900-22-014561 · ownership.xml · derivative · entry 1 French Anna Louise · CIK 0001871871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,045 Underlying: Voting Common Stock · 78,045 shares Expires 2032-03-21 F1 · derivative.exercise_date: 1/3rd of the shares subject to the option shall vest on December 7, 2022, and 1/3rd of the shares subject to the option shall vest on each anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.